Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients
with metastatic PC still receive palliative care. Here, we report the efficacy and safety of …

Pancreatic ductal adenocarcinoma is one of the most aggressive and lethal cancers.
Surgical resection is the only curable treatment option, but it is available for only a small …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers with a dismal
prognosis for the patient. This is due to limited diagnostic options for the early detection of …

Gemcitabine (GEM) is among the most used chemotherapies for advanced malignancies
including non-small cell lung cancer. The clinical efficacy of GEM is, however, downplayed …

Gemcitabine (GEM) drug resistance remains a difficult challenge in pancreatic ductal
adenocarcinoma (PDAC) treatment. Therefore, identifying a safe and effective treatment …

Chemotherapy is a critical modality in cancer therapy to combat malignant cell proliferation
by directly attacking cancer cells and inducing immunogenic cell death, serving as a vital …

Different evidence has indicated metabolic rewiring as a necessity for pancreatic cancer
(PC) growth, invasion, and chemotherapy resistance. A relevant role has been assigned to …

Simple Summary Pancreatic cancer (PC) is a highly aggressive malignant tumor with a high
mortality rate. Growing evidence shows that long non-coding RNAs (lncRNAs) might …

Pancreatic cancer is the fourth-leading cause of cancer-related deaths and is expected to be
the second-leading cause of cancer-related deaths in Europe and the United States by …

This study aimed to evaluate the potential of exosomes from cancer cells to predict
chemoresistance in pancreatic cancer (PC) and explore the molecular mechanisms through …